Pembrolizumab plus chemotherapy for pleural mesothelioma
Mené sur 440 patients atteints d'un mésothéliome pleural de stade avancé (âge médian : 71 ans ; durée médiane de suivi : 16,2 mois), cet essai multicentrique de phase III évalue l'efficacité, du point de vue de la survie globale, et la toxicité de l'ajout de pembrolizumab à une chimiothérapie standard (sels de platine et pémétrexed)
Pleural mesothelioma is an aggressive and incurable cancer 1 with a rising global incidence, 2 especially in low-income countries. Pleural mesothelioma is always fatal, despite attempts at treatment with many novel agents and routes of delivery. Pleural mesothelioma is typically disseminated in multiple foci along the visceral and parietal pleura, making complete surgical resection impossible. 3 Post-mortem studies found that extrapleural deposits are common, although often clinically silent. 4 Radical surgery for pleural mesothelioma is detrimental and shortened survival significantly in a randomised trial.
The Lancet , commentaire, 2022